114 results about "Tissue specific" patented technology

The invention provides a multi-parameter feature fused vertebral CT image standardization preprocessing method and system. The method comprises the following steps: carrying out initial segmentation on an input original vertebral CT image; carrying out enhancement processing on the image by adopting an anisotropic diffusion filtering algorithm of multi-scale structure perception; establishing a tissue specificity density mapping model of multi-parameter fusion; adopting a self-adaptive segmentation histogram mapping method to map gray distribution of an original image to a standard template; and constructing a rigid-elastic mixed registration model. According to the invention, a complete quality evaluation system is established, the processing quality can be automatically detected and reported, and the reliability of an output result is ensured. By introducing a patient individualized correction mechanism, individual difference information is fully reserved while the standardization effect is ensured, and diagnosis information loss caused by excessive standardization is avoided. The multi-parameter fusion strategy ensures complete reservation of bone tissue density, texture and structure information.

The invention relates to a colorectal cancer MRI image segmentation method and system based on multi-dimensional feature fusion, and relates to the technical field of medical image processing. The method comprises the following steps: firstly, collecting multi-source data of a colorectal cancer patient, preprocessing the data, and constructing a multi-scale feature extraction module to obtain feature data of an image; through a multi-dimensional feature fusion module, features of seven dimensions including texture, shape, gray scale, modal association, life habits, functional metabolism and tissue specificity are integrated, and feature screening and weight distribution are realized in combination with a space-channel attention mechanism; and finally, carrying out feature decoding through a U-Net network, and optimizing a segmentation boundary by adopting a full-connection conditional random field (CRF) of an adaptive potential function. According to the method, multi-modal data integration, multi-scale feature extraction, multi-dimensional feature fusion, attention mechanism enabling, U-Net network decoding and CRF post-processing are combined, so that the accuracy and robustness of colorectal cancer MRI image segmentation are improved.

The present invention relates to a novel lipid compound for tissue-specific delivery, and a lipid nano-particle (LNP) composition comprising the same, the lipid nano-particle comprising a modified lipid compound as a component, according to the present invention, internal active substances are selectively delivered into cells of specific tissues such as lymph nodes, spleen, retina, cancer, brain, liver and the like in vivo, thereby preventing side effects and safely exhibiting a desired level of effect. The tissue-specific non-viral LNP delivery vectors can be effectively used for prevention of infectious diseases and treatment of rare and refractory (hereditary) diseases (diseases which are effectively and selectively delivered to in-vivo targeted sites, such as macular degeneration, diabetic retinal degeneration, hereditary retinal degeneration, cancer, cerebral diseases, liver diseases and the like).

The invention discloses a recombinant adeno-associated virus vector for targeted delivery of VEGF-C (vascular endothelial growth factor-C) and application of the recombinant adeno-associated virus vector in promoting endocardial differentiation to treat coronary heart disease. The rAAV vector comprises transgene for coding VEGF-C protein or VEGF-C protein functional variant and a tissue-specific promoter operably connected to the transgene, wherein the tissue specific promoter is capable of driving the transgene to be specifically expressed in the heart endothelial cells. According to the treatment method developed by the invention, specific expression of the Vegfc gene in the heart is driven by using an ICAM2 promoter with targeting to endothelial cells, and a remarkable curative effect is shown in a myocardial infarction model mouse. The therapeutic scheme provides a new effective strategy for intervention and treatment of myocardial infarction and chronic heart failure, and has the advantages of high safety, long gene expression duration, extremely low immune response to a host and the like.

The present application relates to the technical field of bioinformatics, and particularly relates to a method for constructing a biological age prediction model based on DNA methylation. The method comprises the following steps: obtaining whole genome methylation sequencing data of a human peripheral blood sample; classifying cell subpopulations of the human peripheral blood sample, and performing single-cell RNA sequencing processing on each cell subpopulation to obtain single-cell sequencing data including lymphocytes, neutrophils and monocytes; performing tissue-specific analysis on CpG sites within a range of 2000 base pairs upstream and downstream of each cell subpopulation-specific transcription factor binding site according to the single-cell sequencing data and the whole genome methylation sequencing data to obtain candidate marker site data. The present application can provide strong support for early detection of accelerated aging, prediction of related disease risks and guidance of precision medicine.

The invention discloses a nucleic acid construct for inducing DDB2 gene silencing and application of the nucleic acid construct. The designed targeted expression system based on the adeno-associated virus (AAV) vector is higher in specificity, non-target tissue can be prevented from being interfered, the tissue specificity of gene intervention is improved, and the off-target risk is small; the shRNA has high stability and processing efficiency, reduces immune response and interference effect, has high expression efficiency and strong histocompatibility, and is suitable for long-term expression intervention in vivo.

Particulated and reconstituted tissues comprising small, densely packed tissue microparticles encapsulated in a tissue specific promoting gel packed at a percolation threshold that can be transplanted into damaged tissue thereby facilitating regeneration following trauma to the tissue. The engineered microparticle construct for tissue replacement and repair, as taught herein, provides numerous benefits including (1) encouraging a regenerative response in damaged tissue regions, (2) mimicking the structural support of native tissue, (3) establishing an environment that promotes attachment, migration, and differentiation of infiltrating stem cells, and (4) providing a source of growth factors and other anti-catabolic growth factors and cytokines. Tissue specific microparticles packed together at, or past, their percolation threshold will provide the necessary mechanical environment and to best recapitulate and integrate with native tissue. The packing of microparticles, derived from the ECM of native tissue to a concentration past the percolation point will yield both the necessary biochemical and biomechanical properties necessary for reconstituting a specific tissue.

The present invention relates to pharmaceutical compounds, compositions, and methods, particularly as they relate to compositions and methods for treating and / or preventing proliferative disorders associated with TGFβR1 activity, such as cancer or fibrosis. The present invention provides compounds of Formula (I) and Formula (II) as further described herein, which have an acidic moiety that enhances tissue specificity to target tissues and organs. The present invention includes pharmaceutical compositions, pharmaceutical combinations, and methods of using these compounds to treat disorders including cancer or fibrosis.

The present invention relates to: an AAV-based PDE6B viral vector for treating retinitis pigmentosa, the AAV-based PDE6B viral vector containing a tissue-specifically expressed PDE6A promoter; and a use of thereof, and provides a gene therapy for treating retinitis pigmentosa caused by PDE6B gene deficiency. The in vivo therapeutic efficacy of seven types of AAV5-PDE6B vectors was confirmed using an AAV by using a PDE6A promoter that is tissue-specifically expressed in photoreceptor rod cells that develop retinitis pigmentosa. An AAV5-PDE6A-450-PDE6B vector was selected as a candidate due to exhibiting strong tissue-specific expression in photoreceptor rod cells under even off-target conditions, unlike the gene expression characteristics of an AAV5-CMV-PDE6B vector, and was tested so as to be usable in the development of a gene therapeutic agent for treating PDE6B-deficient retinitis pigmentosa patients. Therefore, the present invention, related to AAV5-PDE6B for retinitis pigmentosa treatment and containing a tissue-specifically expressed PDE6A promoter, provides retinitis pigmentosa patients with an important treatment option having improved safety, and can be expected to have fundamental therapeutic effects compared to conventional treatments.

The present invention is directed to a personalized in vitro immune response simulation system, including: a plurality of containers, each container including a culture of tissue-specific cells and endothelial cells in fluid contact with the tissue-specific cells; a liquid medium comprising at least about 25% serum or serum replacement (SR); immune cells suspended in the liquid medium; and a linkage system establishing fluidic coupling between the plurality of containers, allowing the liquid medium to flow through the linkage system, wherein the system is an isogenic system. The present invention further provides methods for preparation of such a system, and for uses thereof.

The invention relates to the technical field of medical image processing, and discloses a cardiovascular plaque component unmarked recognition system and method, and the system comprises a data collection unit, a time domain and frequency domain combined feature extraction algorithm module, a data processing unit, a data transmission unit, a three-dimensional imaging unit and a background processing unit. The time domain and frequency domain combined feature extraction algorithm module maps original measurement pulse sound pressure data to a Hilbert function space to form multi-dimensional feature representation, a tissue specificity functional constraint model is constructed, and multi-scale feature integration is achieved through geodesic distance calculation; the data processing unit generates three kinds of tissue simulation data based on a dual-wavelength optical absorption spectrum principle; the three-dimensional imaging unit obtains different phase data in a two-dimensional rotation acquisition mode, a three-dimensional image is generated through a multi-wavelength optical component decomposition imaging algorithm, a contrast agent or a marker does not need to be used, and accurate distinguishing of a lipid core, a calcification area and a basic tissue is achieved.

The present invention provides constructs comprising a transgene operably linked to a novel tissue-specific maize promoter selected from ris2, Ihcb10, nas2, aa2m, and expb14. Methods of using the constructs to drive tissue-specific transgene expression in a maize plant are provided. Maize plants comprising the constructs or made by the methods are also provided.

The invention discloses an effect of TMEM159 in preparation of a medicine for treating cerebral ischemia reperfusion injury. According to the application disclosed by the invention, molecular biology experiments find that the expression of the TMEM159 in cerebral ischemia reperfusion brain tissues is reduced, and single cell sequencing data in a public database shows that the TMEM159 is mainly expressed in neuronal cells; an AAV9-mediated nerve cell specific TMEM159 overexpression adeno-associated virus vector is further constructed to verify the application of TMEM159 as a treatment target, and the result shows that the TMEM159 overexpression can reduce the cerebral infarction area caused by cerebral ischemia and reduce the cell apoptosis level; therefore, the invention provides a new therapeutic target and medicine for the cerebral ischemia disease, and the TMEM159 overexpression adeno-associated virus provided by the invention has the advantages of long-term expression, low toxicity, low immunogenicity, high tissue specificity and the like, and has good application prospects and transformation values.

Described herein are recombinant viral genomes comprising a nucleotide sequence encoding a telomerase reverse transcriptase (TERT) operably linked to a tissue-specific and / or organ-specific promoter. Aspects described herein may be used in the treatment of conditions associated with shortened telomere length, such as pulmonary fibrosis, myocardial infarction and conditions associated therewith.

Tissue-specific progenitor cells representing the endoderm, ectoderm, and mesoderm lineages are generated from pluripotent sources. Progenitor cell generation is accomplished by contacting pluripotent stem cells with tissue-specific exosomes, microRNAs, proteins, and peptides, obtained by stressing the tissue under in vitro conditions. In vitro-generated tissue organoids are used as a source of "differentiation factors" for generating individualized progenitor cells. For example, to generate lung progenitor cells, allogeneic stem cells are implanted into decellularized cadaveric lung tissue to form lung structures, which are then exposed to various cellular stressors and conditioned media to differentiate the pluripotent stem cells into progenitor cells. Extracellular matrix can be obtained from decellularized structures seeded with regenerating cells and used to generate organoids, which are then subjected to stress to produce differentiation factors.

The present disclosure relates to a method of isolating extracellular vesicles directly from human tissues. The invention further relates to a method of identifying disease and tissue specific membrane proteins on extracellular vesicles by membrane isolation and proteomic analysis. The invention further relates to methods of diagnosing diseases by capturing extracellular vesicles by the use of disease specific membrane proteins from body fluids, and detecting or analyzing molecular signatures (proteome, DNA, and RNA) on captured extracellular vesicles. Moreover, the present invention relates to kits, apparatus and software required for implementing aforementioned methods.

The present disclosure relates to a promoter that is expressed in a tissue-specific manner and uses thereof. Specifically, the promoter of the present disclosure is expressed specifically in the fruit and axillary meristem of a plant. When a fruit-producing plant is transformed with the promoter of the present disclosure, it is possible to breed a variety capable of accumulating useful products in the fruit or producing parthenocarpic fruits, without affecting other vegetative organs.

The application discloses a silk material with a cell proliferation function and application thereof, the functional material is expressed by a human type I collagen truncated fragment in a middle silk gland of a domestic silkworm, a sericin promoter is used as a tissue-specific promoter to drive specific expression of an exogenous gene in the middle silk gland, and finally the exogenous gene is combined with sericin protein and is secreted to outside of the body, the exogenous protein can be separated after a certain treatment of a cocoon, and the expression product can keep biological activity. The silk material is used to prepare a hydrogel, has a function of promoting wound healing, and can be applied to aspects of promoting skin regeneration and repair, bone graft substitutes, cartilage reconstruction, artificial skin and the like.

The present disclosure provides, among other things, methods and compositions in which a nucleic acid sequence includes a mammalian scaffold matrix attachment region (S / MAR) operably linked with a coding sequence. The present disclosure provides S / MARs useful in expression vectors (e.g., for use in gene therapy approaches) to achieve a particular, improved, or target level, duration, and / or tissue specificity of expression of an operably linked coding sequence.

The present disclosure relates to compositions and methods for targeting vesicles to specific tissues and cell types. Also disclosed are compositions and methods for delivering therapeutic molecules, including nucleic acids and nucleic acid derivatives, to specific cells or tissues using vesicles having cell and tissue specific targeting moieties expressed on the surface of the vesicles.

The present application relates to the technical field of health care informatics, in particular to a system for predicting depression of teenagers, comprising an acoustic characteristic representation module, including a co-integrated ultrasonic transducer array and electroencephalogram electrode, an electrode substrate embedded with an acoustic impedance sensor, and a temperature-sensitive acoustic coupling adhesive layer on the surface of the electrode substrate; a multi-layer medium acoustic modeling module: used for establishing an accurate head tissue acoustic transmission model according to individual anatomical structure characteristics, for quantifying the frequency dispersion effect generated when the electroencephalogram signal propagates in different tissue layers, etc.; solving the problem that in the prior art, due to the change of the myelin sheath thickness of teenagers, the tissue-specific dispersion has a systematic influence on the functional connection network, resulting in that the depression-related network abnormalities and the development-related transmission changes cannot be distinguished.

Provided are a tissue tracing method for cell-free DNA, a tissue lesion risk notification method, a cell-free DNA-based cancer risk indication method, a cell-free DNA-based gestational disease risk indication method, a cell-free DNA-based receptor tolerance risk notification method, a disease treatment effect evaluation or prognosis method and apparatus, an electronic device, a computer-readable storage medium, a computer program product and a computer program. The tissue tracing method for cell-free DNA comprises: acquiring a tissue-specific expression gene set of a tissue; acquiring first distribution information of cell-free DNA derived from a sample on specific regions of genes in the tissue-specific expression gene set; and, on the basis of the first distribution information, acquiring a tissue contribution index of the tissue in the cell-free DNA, so as to trace the tissue of the cell-free DNA, wherein the specific regions comprise transcription start site (TSS) regions.

The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in liver tissues.

The invention relates to the technical field of medical care informatics, in particular to a teenager depression prediction system. Comprising an acoustic characteristic characterization module, the acoustic characteristic characterization module comprises an ultrasonic transducer array and electroencephalogram electrode co-integration, an acoustic impedance sensor is embedded in an electrode substrate, and a temperature-sensitive acoustic coupling adhesive layer is arranged on the surface of the electrode substrate; the multi-layer medium acoustic modeling module is used for establishing an accurate skull tissue acoustic transmission model according to the characteristics of an individual anatomical structure, and is used for quantifying the frequency dispersion effect and the like generated when the electroencephalogram signals are transmitted in different tissue layers; the problem that depression-related network abnormity and development-related transmission change cannot be distinguished due to systematic influence of tissue-specific dispersion on a functional connection network due to teenager myelin sheath thickness change in the prior art is solved.

The invention discloses a methylation marker identification method for free DNA (deoxyribonucleic acid), which comprises the following steps of: identifying three types of differential methylation regions of abnormal tissues relative to normal control tissues on the basis of the fragment methylation level of whole genome methylation sequencing data; based on the abnormal tissue M-DMR set and the normal control tissue-specific low-methylation region set, identifying a region set in which the tissue-specific low-methylation region is not changed in the abnormality generation process; on the basis of the abnormal tissue U-DMR set and other normal tissue specific low methylation region sets, identifying that a non-tissue specific high methylation region is converted into a region set similar to other normal tissue specific low methylation regions in the abnormality generation process; a set of aberrant DMRs, NT-DMRs, that fall within a non-tissue-specific region on the genome are identified. The novel and accurate methylation mark recognition method is provided, the methylation set area recognized through the method is highly related to the abnormal tissue, and tools and data support can be provided for recognition of the abnormal tissue.

A method of identifying a biomarker present in a defined category of tissue in an organism at an elevated level when compared to a level in at least one different category of tissue, wherein the biomarker is detectable on extracellular vesicles secreted from cells of the defined category of tissue. The method comprises the steps of: (i) identifying a candidate biomarker; (ii) providing a binding agent capable of specifically binding to the candidate biomarker identified in step i. (iii) detecting the presence of a candidate biomarker on extracellular vesicles obtained from a sample of defined categories of tissue by binding a binding agent to the candidate biomarker in the sample, where the candidate biomarker is not present on the extracellular vesicles obtained from the sample of defined categories of tissue, compared to the extracellular vesicles from at least one different category of tissue of the organism, extracellular vesicles from defined categories of tissue preferentially bind to a binding agent; and (iv) selecting the candidate biomarker as a biomarker present at an elevated level in the defined category of tissue. Also provided are methods of enriching a biological sample comprising a mixture of extracellular vesicles to generate an enriched fraction of extracellular vesicles from defined categories of tissue. Also provided are methods of analyzing the contents of extracellular vesicles in an enriched fraction of extracellular vesicles from defined categories of tissue.

The invention relates to application of uridine in the development process of a medicine for preventing and treating diabetic nephropathy and in the medicine. Clinical metabonomics identification and animal experiment verification prove that uridine is a key active metabolite of DKD, the treatment effect of uridine has the characteristics of multiple targets and tissue specificity, and a new solution for research and development of metabolic drugs based on DKD is provided; through pharmacodynamic research of uridine and exploration of a protection mechanism, various application scenes of uridine in the research and development process of medicines for preventing and / or reducing diabetic nephropathy patients are further explored, so that the application of uridine in DKD medicines and the research and development process of the medicines is wider, and a wider prospect is provided for later research and development of the DKD medicines.

The application belongs to the technical field of biological medicine, and specifically provides a soluble microneedle transdermal drug delivery system and a preparation method thereof. The nanocapsule is PEGylated, so as to improve the biocompatibility of the nanocapsule. The obtained soluble microneedle transdermal drug delivery system comprises a substrate and a needle body, and both of them load the nanocapsule by using a biocompatible degradable polymer component. The system has strong tissue specificity, avoids the toxic and side effects of drugs on normal tissues, reduces the pain of patients in the treatment process, and improves the compliance of patients in the treatment process. The microneedle in the system can dissolve in the skin and release drugs, and will not cause damage to the human body. The system has low residual and low biological pollution risk, and has higher drug loading capacity and higher safety compared with the coating microneedle and the hollow microneedle. The system has excellent biocompatibility, high viscoelasticity, plasticity and permeability.